89bio Files DEF 14A on Executive Compensation
| Field | Detail |
|---|---|
| Company | 89bio, Inc. |
| Form Type | DEF 14A |
| Filed Date | Apr 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, equity-awards, sec-filing, def-14a
TL;DR
89bio's 14A is out, detailing exec pay & stock awards for 2024. Check the numbers.
AI Summary
89bio, Inc. filed its DEF 14A on April 15, 2025, detailing executive compensation and corporate governance for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted, outstanding equity awards, and changes in the value of these awards for both principal executive officers (PEO) and non-PEO/NEO members. Specific financial figures related to these compensation elements are presented within the summary compensation tables.
Why It Matters
This filing provides transparency into how 89bio compensates its top executives, which can influence investor decisions regarding the company's financial health and management's alignment with shareholder interests.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but the details on executive compensation and equity awards can reveal potential risks related to shareholder dilution or management incentives.
Key Numbers
- 2024 — Fiscal Year (The period for which executive compensation and equity awards are detailed.)
- 2023 — Fiscal Year (Comparative compensation data may be available for this prior year.)
- 2022 — Fiscal Year (Comparative compensation data may be available for this prior year.)
Key Players & Entities
- 89bio, Inc. (company) — Filer of the DEF 14A
- 0001785173 (company) — Central Index Key for 89bio, Inc.
- 20250415 (date) — Filing date of the DEF 14A
- 2024-12-31 (date) — Fiscal year end for compensation details
FAQ
What is the total reported compensation for the Principal Executive Officer (PEO) in 2024?
The filing details various components of compensation, including salary, stock awards, option awards, non-equity incentive plan compensation, and non-qualified deferred compensation earnings. Specific total figures for the PEO in 2024 would be found within the Summary Compensation Table.
How many outstanding equity awards were granted to non-PEO/NEO members in 2024?
The filing references 'YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:NonPeoNeoMember' for the period 2024-01-01 to 2024-12-31, indicating data on outstanding equity awards for this group.
What was the change in the value of outstanding equity awards granted in prior years for PEO members during 2024?
The filing includes 'ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:PeoMember' for the period 2024-01-01 to 2024-12-31, which would contain this information.
When was the DEF 14A filing submitted to the SEC?
The filing was submitted on April 15, 2025, as indicated by the accession number and header information.
What is the primary business of 89bio, Inc. according to the filing?
89bio, Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 15, 2025 regarding 89bio, Inc..